J&J's consumer health spinout has a new name, Kenvue, and a modern look for its well-known portfolio of brands including Tylenol and Neutrogena.

J&J de­buts Ken­vue as new name for $15B con­sumer health busi­ness spin­off

John­son & John­son’s con­sumer health com­pa­ny has a new name, iden­ti­ty and pur­pose. Ken­vue is a com­bi­na­tion of “ken” mean­ing knowl­edge and “vue” a homonym of view, the com­pa­ny said on Wednes­day.

The $15 bil­lion con­sumer spin­off with house­hold sta­ple brands in­clud­ing Neu­tro­ge­na, Tylenol, Band-Aid and a line­up of ba­by care prod­ucts is set to be­come a sep­a­rate pub­licly trad­ed com­pa­ny by No­vem­ber 2023.

Along with the name, J&J is adopt­ing a dark green graph­i­cal­ly de­signed “K” as the brand lo­go. The squared-up rec­tan­gle in the first half of the let­ter is meant to rep­re­sent sci­en­tif­ic pre­ci­sion, while the round­ed sec­ond half re­sem­bling a side­ways heart shape is meant to evoke the warmth of care, J&J said in a press re­lease.

In an in­tro­duc­to­ry video, the “K” changes col­ors along­side its prod­ucts — turn­ing dif­fer­ent shades of blue for Neu­tro­ge­na and Lis­ter­ine, then yel­low-or­ange for Ba­by Sham­poo and red for Tylenol.

J&J used a small core team to de­vel­op and screen thou­sands of names be­fore set­tling on Ken­vue, a J&J Con­sumer Health spokesper­son said in an email. The name need­ed to work across lan­guages and cul­tures and clear trade­mark hur­dles, while al­so be­ing dis­tinc­tive and com­mu­ni­cat­ing core brand propo­si­tions, she said.

“We want­ed to cre­ate some­thing that could el­e­vate Ken­vue as a mod­ern, dig­i­tal-first com­pa­ny as well as cap­ture and show­case our in­cred­i­ble pur­pose in an in­stant,” she said, adding that the curves in the sec­ond half of the K lo­go are re­flect­ed in the prod­ucts, ad­vis­ing “look close­ly to note the soft curves rep­re­sen­ta­tive of our Tylenol and Band-Aid brands.”

Thibaut Mon­gon

The new Ken­vue pur­pose is “Re­al­ize the ex­tra­or­di­nary pow­er of every­day care” which J&J con­sumer health CEO des­ig­nate Thibaut Mon­gon ex­plained in the press re­lease as re­lat­ing to “dai­ly self-care rit­u­als add up over time and have a pro­found cu­mu­la­tive im­pact on your well­be­ing. This is the ex­tra­or­di­nary pow­er of every­day care.”

J&J is the lat­est big phar­ma com­pa­ny to spin off its con­sumer health busi­ness, fol­low­ing on the heels of GSK and Pfiz­er’s joint con­sumer com­pa­ny Ha­le­on this sum­mer. Ha­le­on be­gan trad­ing as a sep­a­rate com­pa­ny in Ju­ly, and adopt­ed its own al­so bright green col­or in its black and green name lo­go.

J&J re­port­ed 2021 con­sumer health sales of $14.6 bil­lion, com­pared to $52 bil­lion for its much larg­er phar­ma busi­ness. In Ju­ly, it re­port­ed Q2 sales of $3.8 bil­lion for con­sumer health and $13.3 bil­lion for phar­ma prod­ucts. J&J’s third busi­ness unit, med­ical de­vices, notched sales of $27 bil­lion in 2021 and $7 bil­lion in the most re­cent sec­ond quar­ter.

The pro­posed new con­sumer com­pa­ny name comes as J&J le­gal bat­tles con­tin­ue over one of its key con­sumer prod­ucts John­son & John­son Ba­by Pow­der. Af­ter years of lit­i­ga­tion with tens of thou­sands of cas­es still in court over al­le­ga­tions of its talc-based pow­der, J&J moved to spin out the talc li­a­bil­i­ties in­to a sep­a­rate com­pa­ny and filed for bank­rupt­cy ear­li­er this year.

The bank­rupt­cy move was ini­tial­ly ap­proved, al­though is now be­ing chal­lenged by plain­tiffs. J&J had al­ready re­moved talc from its US prod­ucts, but said in Au­gust it will switch to all-corn­starch ba­by pow­der prod­ucts glob­al­ly by the first quar­ter of 2023.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image: uk-cpi.com)

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.